US OptionsDetailed Quotes
RXRX241206P6500
- 0.03
- -0.04-57.14%
15min DelayClose Dec 4 16:00 ET
0.09High0.03Low
0.09Open0.07Pre Close4 Volume165 Open Interest6.50Strike Price24.00Turnover110.43%IV9.26%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.1088Delta0.3370Gamma237.67Leverage Ratio-0.0248Theta0.0000Rho-25.86Eff Leverage0.0009Vega
Recursion Pharmaceuticals Stock Discussion
“The evolution of precision and personalized treatment options for oncology patients provide promising alternatives,” says William McKean, MD, Clinical Investigator at START Mountain Region in Salt Lake City, Utah. “We are so pleased to be working with Recursion as a participating site in the DAHLIA trial, and look forward to advancing the science of cancer treatment.”
$Recursion Pharmaceuticals (RXRX.US)$
$NVIDIA (NVDA.US)$
Goldman Sachs also pointed out in a previous report that by 2025, investors are expected to shift from AI infrastructure to a broader "t...
No comment yet